FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913247824> ?p ?o ?g. }

• W2913247824 endingPage "S365" @default.
• W2913247824 startingPage "S365" @default.
• W2913247824 abstract "IntroductionBlood management and infectious disease mitigation are essential for success with allogeneic stem cell transplant (alloSCT). We sought to investigate the safety profile of a proactive infection mitigation strategy with the use of pathogen-inactivated (PI) platelets (PLT) during the alloSCT peri-engraftment period in the era of restrictive blood transfusion.MethodsWe retrospectively analyzed data from patients undergoing alloSCT that received prophylactic red blood cell (RBC) and PLT transfusion triggered by a hemoglobin of 8 g/dL and PLT count of 15,000 PLT/mL. When available, PI PLT (non-irradiated) were used starting November 2016 until March 2018 (study timeframe). Statistical analysis was performed using SAS 9.4 (Cary, NC). Patients characteristics and clinical parameters were summarized using mean and standard deviation or median and range for continuous data, and frequency and percentage for categorical data. Kaplan-Meier analysis was used to estimate progression-free survival (PFS) and overall survival (OS) from day of transplant. A two-sided logrank test was used to compare across strata using p<0.05 as significance cut-off. Univariate Cox proportional hazard regression analyses were performed to assess the effect of continuous explanatory variables.ResultsSixty-eight patients received alloSCT. Median age at transplant was 55 years (range [R], 18-73). Peripheral blood stem cells were the graft source in all but one patient. Donor source was a matched related, 10/10 matched unrelated (MUD), 9/10 MUD and haploidentical donor in 30.9%, 44.1%, 2.9%, and 22.1% of cases, respectively. Myeloablative conditioning was used in 45.6% of patients. Indication for alloSCT was a myeloid or lymphoid disorder in 64.7% and 35.3% of cases. Median time to neutrophil and PLT engraftment was 12 (R, 10-35) and 12 days (R, 8-120), respectively. Pre-alloSCT RBC alloimmunization was present in 11.8% of patients. Cumulative incidence of grades II-IV acute and chronic graft-versus-host disease (GVHD) was 20.6% and 22.1%, respectively. PI PLT were used in 73.5 % patients. There were no cases of transfusion associated graft failure (GF) or GVHD. Bacteremia occurred in 10.0% and 22.1% of patients by 30 days and 100 days post-alloSCT, respectively, and were both associated with worse OS (both p<0.001). Persistent RBC transfusions beyond 30 days post-transplant was associated with both inferior PFS and OS (p=0.04 and p=0.0009, respectively).ConclusionsRestrictive prophylactic transfusion thresholds in alloSCT recipients is feasible. Limited PI PLT transfusion was not associated with transfusion-attributable GVHD, GF or infectious complications. Future prospective studies should determine the short term hemostatic efficacy and long term post-alloSCT outcomes with restrictive transfusion criteria in an era of expanding PI product use. Blood management and infectious disease mitigation are essential for success with allogeneic stem cell transplant (alloSCT). We sought to investigate the safety profile of a proactive infection mitigation strategy with the use of pathogen-inactivated (PI) platelets (PLT) during the alloSCT peri-engraftment period in the era of restrictive blood transfusion. We retrospectively analyzed data from patients undergoing alloSCT that received prophylactic red blood cell (RBC) and PLT transfusion triggered by a hemoglobin of 8 g/dL and PLT count of 15,000 PLT/mL. When available, PI PLT (non-irradiated) were used starting November 2016 until March 2018 (study timeframe). Statistical analysis was performed using SAS 9.4 (Cary, NC). Patients characteristics and clinical parameters were summarized using mean and standard deviation or median and range for continuous data, and frequency and percentage for categorical data. Kaplan-Meier analysis was used to estimate progression-free survival (PFS) and overall survival (OS) from day of transplant. A two-sided logrank test was used to compare across strata using p<0.05 as significance cut-off. Univariate Cox proportional hazard regression analyses were performed to assess the effect of continuous explanatory variables. Sixty-eight patients received alloSCT. Median age at transplant was 55 years (range [R], 18-73). Peripheral blood stem cells were the graft source in all but one patient. Donor source was a matched related, 10/10 matched unrelated (MUD), 9/10 MUD and haploidentical donor in 30.9%, 44.1%, 2.9%, and 22.1% of cases, respectively. Myeloablative conditioning was used in 45.6% of patients. Indication for alloSCT was a myeloid or lymphoid disorder in 64.7% and 35.3% of cases. Median time to neutrophil and PLT engraftment was 12 (R, 10-35) and 12 days (R, 8-120), respectively. Pre-alloSCT RBC alloimmunization was present in 11.8% of patients. Cumulative incidence of grades II-IV acute and chronic graft-versus-host disease (GVHD) was 20.6% and 22.1%, respectively. PI PLT were used in 73.5 % patients. There were no cases of transfusion associated graft failure (GF) or GVHD. Bacteremia occurred in 10.0% and 22.1% of patients by 30 days and 100 days post-alloSCT, respectively, and were both associated with worse OS (both p<0.001). Persistent RBC transfusions beyond 30 days post-transplant was associated with both inferior PFS and OS (p=0.04 and p=0.0009, respectively). Restrictive prophylactic transfusion thresholds in alloSCT recipients is feasible. Limited PI PLT transfusion was not associated with transfusion-attributable GVHD, GF or infectious complications. Future prospective studies should determine the short term hemostatic efficacy and long term post-alloSCT outcomes with restrictive transfusion criteria in an era of expanding PI product use." @default.
• W2913247824 created "2019-02-21" @default.
• W2913247824 creator A5000230874 @default.
• W2913247824 creator A5003799076 @default.
• W2913247824 creator A5009980957 @default.
• W2913247824 creator A5013109056 @default.
• W2913247824 creator A5015305880 @default.
• W2913247824 creator A5029363412 @default.
• W2913247824 creator A5037199263 @default.
• W2913247824 creator A5057178417 @default.
• W2913247824 creator A5058524502 @default.
• W2913247824 creator A5062298311 @default.
• W2913247824 creator A5069675293 @default.
• W2913247824 creator A5083730552 @default.
• W2913247824 creator A5086517180 @default.
• W2913247824 creator A5090669888 @default.
• W2913247824 creator A5091021372 @default.
• W2913247824 creator A5091113228 @default.
• W2913247824 date "2019-03-01" @default.
• W2913247824 modified "2023-09-24" @default.
• W2913247824 title "Restrictive Transfusions in the Era of Pathogen-Inactivated Platelets: A Single Center Experience" @default.
• W2913247824 doi "https://doi.org/10.1016/j.bbmt.2018.12.591" @default.
• W2913247824 hasPublicationYear "2019" @default.
• W2913247824 type Work @default.
• W2913247824 sameAs 2913247824 @default.
• W2913247824 citedByCount "0" @default.
• W2913247824 crossrefType "journal-article" @default.
• W2913247824 hasAuthorship W2913247824A5000230874 @default.
• W2913247824 hasAuthorship W2913247824A5003799076 @default.
• W2913247824 hasAuthorship W2913247824A5009980957 @default.
• W2913247824 hasAuthorship W2913247824A5013109056 @default.
• W2913247824 hasAuthorship W2913247824A5015305880 @default.
• W2913247824 hasAuthorship W2913247824A5029363412 @default.
• W2913247824 hasAuthorship W2913247824A5037199263 @default.
• W2913247824 hasAuthorship W2913247824A5057178417 @default.
• W2913247824 hasAuthorship W2913247824A5058524502 @default.
• W2913247824 hasAuthorship W2913247824A5062298311 @default.
• W2913247824 hasAuthorship W2913247824A5069675293 @default.
• W2913247824 hasAuthorship W2913247824A5083730552 @default.
• W2913247824 hasAuthorship W2913247824A5086517180 @default.
• W2913247824 hasAuthorship W2913247824A5090669888 @default.
• W2913247824 hasAuthorship W2913247824A5091021372 @default.
• W2913247824 hasAuthorship W2913247824A5091113228 @default.
• W2913247824 hasBestOaLocation W29132478241 @default.
• W2913247824 hasConcept C126322002 @default.
• W2913247824 hasConcept C141071460 @default.
• W2913247824 hasConcept C2780073493 @default.
• W2913247824 hasConcept C28328180 @default.
• W2913247824 hasConcept C54355233 @default.
• W2913247824 hasConcept C71924100 @default.
• W2913247824 hasConcept C86803240 @default.
• W2913247824 hasConcept C89560881 @default.
• W2913247824 hasConcept C90924648 @default.
• W2913247824 hasConceptScore W2913247824C126322002 @default.
• W2913247824 hasConceptScore W2913247824C141071460 @default.
• W2913247824 hasConceptScore W2913247824C2780073493 @default.
• W2913247824 hasConceptScore W2913247824C28328180 @default.
• W2913247824 hasConceptScore W2913247824C54355233 @default.
• W2913247824 hasConceptScore W2913247824C71924100 @default.
• W2913247824 hasConceptScore W2913247824C86803240 @default.
• W2913247824 hasConceptScore W2913247824C89560881 @default.
• W2913247824 hasConceptScore W2913247824C90924648 @default.
• W2913247824 hasIssue "3" @default.
• W2913247824 hasLocation W29132478241 @default.
• W2913247824 hasOpenAccess W2913247824 @default.
• W2913247824 hasPrimaryLocation W29132478241 @default.
• W2913247824 hasRelatedWork W2001851581 @default.
• W2913247824 hasRelatedWork W2022520514 @default.
• W2913247824 hasRelatedWork W2082430176 @default.
• W2913247824 hasRelatedWork W2092353921 @default.
• W2913247824 hasRelatedWork W2159038491 @default.
• W2913247824 hasRelatedWork W2315136905 @default.
• W2913247824 hasRelatedWork W2601571492 @default.
• W2913247824 hasRelatedWork W3093513609 @default.
• W2913247824 hasRelatedWork W3100358636 @default.
• W2913247824 hasRelatedWork W4291007265 @default.
• W2913247824 hasVolume "25" @default.
• W2913247824 isParatext "false" @default.
• W2913247824 isRetracted "false" @default.
• W2913247824 magId "2913247824" @default.
• W2913247824 workType "article" @default.